Edwards Lifesciences (EW) Stock Statistics & Valuation Metrics

Edwards Lifesciences has a market cap or net worth of CHF40.65B. The enterprise value is CHF48.17B.

Edwards Lifesciences has 575,800,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Edwards Lifesciences’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 11.40%.

The current PE Ratio of Edwards Lifesciences is 46.3. Edwards Lifesciences’s PEG ratio is -0.63.

In the last 12 months, Edwards Lifesciences had revenue of 6.07B and earned 1.07B in profits. Earnings per share was 1.84.

In the last 12 months, operating cash flow was 1.36B and capital expenditures -269.10M, giving a free cash flow of 1.09B billion.

Edwards Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―

Edwards Lifesciences upcoming earnings date is Jul 23, 2026, After Close (Confirmed).

Edwards Lifesciences as a current ratio of 3.72, with Debt / Equity ratio of 6.81%

In the past 12 months, Edwards Lifesciences has paid 216.90M in taxes.

Edwards Lifesciences EV to EBITDA ratio is 33.31, with an EV/FCF ratio of 35.67.

Edwards Lifesciences has CHF3.67B in cash and marketable securities with CHF702.90M in debt, giving a net cash position of CHF2.97B billion.

Gross margin is 78.01%, with operating margin of 26.97%, and net profit margin of 17.69%.

The average price target for Edwards Lifesciences is CHF77.98, which is 11.43% higher than the current price. The consensus rating is Strong Buy